Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Protein-functionalized and intrinsically radiolabeled [Re]ReO nanoparticles: advancing cancer therapy through concurrent radio-photothermal effects.
Eur J Nucl Med Mol Imaging
January 2025
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India.
Purpose: Enhancing therapeutic effectiveness is crucial for translating anticancer nanomedicines from laboratory to clinical settings. In this study, we have developed radioactive rhenium oxide nanoparticles encapsulated in human serum albumin ([Re]ReO-HSA NPs) for concurrent radiotherapy (RT) and photothermal therapy (PTT), aiming to optimize treatment outcomes.
Methods: [Re]ReO-HSA NPs were synthesized by a controlled reduction of ReO in HSA medium and extensively characterized.
Imaging Demyelinated Axons After Spinal Cord Injuries with PET Tracer [F]3F4AP.
J Nucl Med
January 2025
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts;
Spinal cord injuries (SCIs) often lead to lifelong disability. Among the various types of injuries, incomplete and discomplete injuries, where some axons remain intact, offer potential for recovery. However, demyelination of these spared axons can worsen disability.
View Article and Find Full Text PDFNovel Dual-Functional Half-Curcumin Analogues as a Fluorescent and PET Probe for β-Amyloid Imaging in the Alzheimer's Disease APP/PS1 Model.
ACS Chem Neurosci
January 2025
School of Medicine, Shanghai University, Shanghai 200444, China.
Noninvasive imaging of β-amyloid is pivotal for the early diagnosis of Alzheimer's disease (AD). While single imaging methods have been extensively studied for detecting Aβ over the past decade, dual-modal probes have received scant attention. In this study, we synthesized and assessed a series of half-curcumin probes, among which demonstrated a high affinity and selectivity for Aβ aggregates.
View Article and Find Full Text PDFDevelopment of a PET Probe Targeting Bromodomain and Extra-Terminal Proteins for In Vitro and In Vivo Visualization.
Pharmaceuticals (Basel)
December 2024
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
Bromodomain and extra-terminal (BET) proteins are critical regulators of gene transcription, as they recognize acetylated lysine residues. The BD1 bromodomain of BRD4, a member of the BET family, has emerged as a promising therapeutic target for various diseases. This study aimed to develop and evaluate a novel C-11 labeled PET radiotracer, [C]YL10, for imaging the BD1 bromodomain of BRD4 in vivo.
View Article and Find Full Text PDFTargeting mutant p53: Evaluation of novel anti-p53 monoclonal antibodies as diagnostic tools.
Sci Rep
January 2025
Department of Microbiology, Tumor and Cell Biology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
About 50% of all cancers carry a mutation in p53 that impairs its tumor suppressor function. The p53 missense mutation p53 (p53 in mice) is a hotspot mutation in various cancer types. Therefore, monoclonal antibodies selectively targeting clinically relevant mutations like p53 could prove immensely value.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!